Loading...
•
Sep 28, 2024
Perrigo Q3 2024 Earnings Report
Delivered solid financial results with operating income growth and margin expansion. Infant Formula business recovery made significant progress.
Key Takeaways
Perrigo reported a decrease in net sales by 3.2% to $1.1 billion, with organic net sales decreasing by 2.4%. However, the company saw significant growth in adjusted operating income, which increased by 21.3% to $182 million. Adjusted diluted EPS increased by 26.6% to $0.81. The infant formula business is recovering, with net sales growth of 3% compared to the prior year quarter and 58% sequentially.
Net sales decreased by 3.2% to $1.1 billion, with a 2.4% decrease in organic net sales.
Adjusted operating income increased by 21.3% to $182 million.
Adjusted diluted EPS increased by 26.6% to $0.81.
Infant formula net sales grew by 3% compared to the prior year quarter and 58% sequentially.
Perrigo
Perrigo
Perrigo Revenue by Segment
Revenue by Segment
Consumer Self-Care Americas Revenue
CapyFin.comConsumer Self-Care International Revenue
CapyFin.com Forward Guidance
The Company expects its fiscal 2024 organic net sales and total net sales outlook to be towards the lower end of their previously stated ranges. The Company reaffirms its adjusted diluted EPS outlook of $2.50 to $2.65.
Positive Outlook
- Gross and operating margin expansion is expected.
- Interest expense of approximately $180 million.
- Full year adjusted tax rate of 19% to 20%.
- Operating cash flow conversion (operating cash flow as a percentage of adjusted net income) of approximately 90% to 100%.
- Reaffirms adjusted diluted EPS outlook of $2.50 to $2.65.
Revenue & Expenses
Visualization of income flow from segment revenue to net income